Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 1;11(3):797.
doi: 10.3390/jcm11030797.

Erythema Migrans-like COVID Vaccine Arm: A Literature Review

Gaia Fasano  1 , Luigi Bennardo  1 , Silvana Ruffolo  2 , Maria Passante  1 , Azzurra Gaia Ambrosio  1 , Maddalena Napolitano  3 , Eugenio Provenzano  2 , Steven Paul Nisticò  1 , Cataldo Patruno  1
Affiliations
Review

Erythema Migrans-like COVID Vaccine Arm: A Literature Review

Gaia Fasano et al. J Clin Med. .

Abstract

COVID Vaccine Arm (CVA) is an adverse drug reaction from mRNA vaccine for SARS-CoV-2. CVA is characterized by erythema and edema on the vaccination site (usually deltoid area) that appears from 5 to 10 days after vaccination and is sometimes associated with itching or pain. The exact etiology of CVA is still unclear, but delayed hypersensitivity against an excipient seems to play an essential role in the pathogenesis of the disease. This work performs a systematic literature review on CVA using three different databases containing articles published until 10 November 2021. The literature review includes eight papers reporting single cases or case series of CVA. Moreover, it also addresses, other cutaneous reactions following COVID 19 vaccinations as well as possible differential diagnosis. CVA migrans-like erythema is characterized by a ring-shaped rash in the injection area, which appears some days after the injection and disappears in about 10 days. This reaction may appear more rapidly in subsequent doses.

Keywords: COVID Vaccine Arm (CVA); COVID-19; Cominarty® Pfizer/BioNTech’s (BNT162b2) vaccine; Erythema migrans-like; Spikevax® Moderna (mRNA-1273) vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Erythematous, edematous, marginated Erythema migrans-like COVID Vaccine Arm eruption 7 days after the first dose of the Moderna vaccine.
Figure 2
Figure 2
Articles selection flowchart.
See this image and copyright information in PMC

References

    1. Jin Y., Yang H., Ji W., Wu W., Chen S., Zhang W., Duan G. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372. doi: 10.3390/v12040372. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention COVID Data Tracker. [(accessed on 12 February 2021)]; Available online: http://covid.cdc.gov/covid-data-tracker/#global-counts-rates.
    1. Fernandez-Nieto D., Hammerle J., Fernandez-Escribano M., Moreno-Del Real C.M., Garcia-Abellas P., Carretero-Barrio I., Solano-Solares E., de-la-Hoz-Caballer B., Jimenez-Cauhe J., Ortega-Quijano D., et al. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. ‘COVID-arm’: A clinical and histological characterization. J. Eur. Acad. Dermatol. Venereol. 2021;35:e425–e427. doi: 10.1111/jdv.17250. - DOI - PMC - PubMed
    1. Gregoriou S., Kleidona I.A., Tsimpidakis A., Nicolaidou E., Stratigos A., Rigopoulos D. ‘COVID vaccine arm’ may present after both mRNA vaccines vaccination. J. Eur. Acad. Dermatol. Venereol. 2021;35:e867–e868. doi: 10.1111/jdv.17614. - DOI - PMC - PubMed
    1. Blumenthal K.G., Freeman E.E., Saff R.R. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N. Engl. J. Med. 2021;384:1273–1277. doi: 10.1056/NEJMc2102131. - DOI - PMC - PubMed

LinkOut - more resources